Abstract
As an alternative to the inconvenient and labor intensive traditional anticoagulants, Factor Xa inhibitors may offer new options for the prevention and treatment of acute coronary syndromes (ACS) and venous thromboembolism (VTE). Fondaparinux, an indirect FXa inhibitor, has equivalent efficacy but decreased bleeding risk. It has been recommended by the American College of Cardiology (ACC)/American Heart Association (AHA) as the preferred anticoagulant in ACS patients with higher bleeding risk managed with a noninvasive strategy. Based on the composite results of several clinical trials, fondaparinux is also recommended for VTE prevention in the setting of major orthopedic surgery. Rivaroxaban, a direct FXa inhibitor, appears to have at least equal efficacy and safety to established anticoagulants in the prevention of VTE. With advantages such as oral administration and a wide therapeutic window, it may provide a useful alternative to current anticoagulants. Ongoing studies are exploring its use in treatment of VTE and ACS, as well as prevention of stroke among patients with atrial fibrillation. In this review, we examine the key recent studies on efficacy and safety of FXa inhibitors in ACS and VTE management.
Keywords: Factor, Xa, inhibitor, rivaroxaban, fondaparinux, anticoagulation, ACS, VTE
Current Vascular Pharmacology
Title: Factor Xa Inhibitors in Acute Coronary Syndromes and Venous Thromboembolism
Volume: 8 Issue: 1
Author(s): Celina M. Yong and Andrew J. Boyle
Affiliation:
Keywords: Factor, Xa, inhibitor, rivaroxaban, fondaparinux, anticoagulation, ACS, VTE
Abstract: As an alternative to the inconvenient and labor intensive traditional anticoagulants, Factor Xa inhibitors may offer new options for the prevention and treatment of acute coronary syndromes (ACS) and venous thromboembolism (VTE). Fondaparinux, an indirect FXa inhibitor, has equivalent efficacy but decreased bleeding risk. It has been recommended by the American College of Cardiology (ACC)/American Heart Association (AHA) as the preferred anticoagulant in ACS patients with higher bleeding risk managed with a noninvasive strategy. Based on the composite results of several clinical trials, fondaparinux is also recommended for VTE prevention in the setting of major orthopedic surgery. Rivaroxaban, a direct FXa inhibitor, appears to have at least equal efficacy and safety to established anticoagulants in the prevention of VTE. With advantages such as oral administration and a wide therapeutic window, it may provide a useful alternative to current anticoagulants. Ongoing studies are exploring its use in treatment of VTE and ACS, as well as prevention of stroke among patients with atrial fibrillation. In this review, we examine the key recent studies on efficacy and safety of FXa inhibitors in ACS and VTE management.
Export Options
About this article
Cite this article as:
Yong M. Celina and Boyle J. Andrew, Factor Xa Inhibitors in Acute Coronary Syndromes and Venous Thromboembolism, Current Vascular Pharmacology 2010; 8 (1) . https://dx.doi.org/10.2174/157016110790226688
DOI https://dx.doi.org/10.2174/157016110790226688 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metabotropic Glutamate Receptors and Interacting Proteins: Evolving Drug Targets
Current Drug Targets Emerging Novel Treatment Strategies for Diabetic Eye Diseases
Current Diabetes Reviews Heterocyclic Secretase Inhibitors for the Treatment of Alzheimer’s Disease: An Overview
Central Nervous System Agents in Medicinal Chemistry Chronic Kidney Disease and Urological Disorders: An Overview
Current Signal Transduction Therapy Lysophosphatidic Acid and Renal Fibrosis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Disaggregating Chaperones: An Unfolding Story
Current Protein & Peptide Science Cardiovascular Morbidity and Mortality in Peripheral Arterial Disease
Current Drug Targets - Cardiovascular & Hematological Disorders Patients with Acute Coronary Syndrome are at High Risk Prior to the Event and Lipid Management is Underachieved Pre- and Post- Hospitalization
Current Vascular Pharmacology Gender Differences in the Effects of Angiotensin Receptor Blockers on Cardiovascular Disease
Current Pharmaceutical Design Developments in Imaging Technologies Related to Hypertensive Cardiovascular Diseases
Current Pharmaceutical Design Persistent Pulmonary Hypertension of the Newborn: Physiology, Hemodynamic Assessment and Novel Therapies
Current Pediatric Reviews Family History and Preclinical Atherosclerosis
Current Hypertension Reviews Molecular Mechanisms of Mineralocorticoid Receptor Antagonism by Eplerenone
Mini-Reviews in Medicinal Chemistry Epidemiology and Management of Acute Kidney Injury in Hepatocellular Carcinoma Patients Undergoing Transcatheter Arterial Chemoembolization
Current Protein & Peptide Science Role of Magnetic Resonance Imaging in Myocardial Iron Assessment
Current Cardiology Reviews Avocado (Persea americana) Seed as a Source of Bioactive Phytochemicals
Current Pharmaceutical Design A Role for Endothelin-1 in Peripheral Vascular Disease
Current Vascular Pharmacology Editorial [Hot topic:Thromboembolism in Patients with Malignancy (Guest Editor: Ioannis Starakis)]
Cardiovascular & Hematological Disorders-Drug Targets Pre- and Post-conditioning in Cardiovascular Surgery
Current Vascular Pharmacology Copy Number Variations with Isolated Fetal Ventriculomegaly
Current Molecular Medicine